Source

TARGETS

ISSNs: 1477-3627, 1878-0989

Source type: journal

Publisher: Elsevier BV

Fully OA: No

DOAJ: No

OpenAlex ID: S4210194224

Haemozoin (malaria pigment): a unique crystalline drug target

2003 · Timothy J. Egan · TARGETS · 79

GPCRs: an update on structural approaches to drug discovery

2003 · Nigel R.A. Beeley, Carleton Sage · TARGETS · 35

Automation of phage display for high-throughput antibody development

2002 · Zoltán Konthur, Gerald Walter · TARGETS · 29

siRNA delivery technologies for mammalian systems

2003 · David B. Rozema, David L. Lewis · TARGETS · 26

High-throughput applications of phage display in proteomic analyses

2003 · Zoltán Konthur, Reto Crameri · TARGETS · 26

Stealth sensors: real-time monitoring of the cell cycle

2003 · Nick Thomas, IanD. Goodyer · TARGETS · 26

Applications of biomolecular interaction analysis in drug development

2002 · Bastian Zimmermann, Claudia Hahnefeld, et al. · TARGETS · 26

Progress in antibody arrays

2003 · Michael J. Taussig, Ulf Landegren · TARGETS · 19

Integrating computer-based de novo drug design and multidimensional filtering for desirable drugs

2002 · Jun Shimada, Sean Ekins, et al. · TARGETS · 17

Tired of the same old grind in the new genomics and proteomics era?

2002 · Patricia E. Garrett, Feng Tao, et al. · TARGETS · 14

Genome-wide mRNA profiling: impact on compound evaluation and target identification in anti-bacterial research

2002 · Christoph Freiberg, Nina A. Brunner · TARGETS · 14

Use of random ribozyme libraries for the rapid screening of apoptosis- and metastasis-related genes

2003 · Laura D. Nelson, Eigo Suyama, et al. · TARGETS · 12

The importance of alternative splicing in the drug discovery process

2003 · Erez Y. Levanon, Rotem Sorek · TARGETS · 12

Targeting VEGF ligands and receptors in cancer

2003 · Ajay K. Malik, Hans-Peter Gerber · TARGETS · 11

What constitutes target validation?

2003 · Norton P. Peet · TARGETS · 10

Protein structure: discovering selective protein kinase inhibitors

2003 · Sean G. Buchanan · TARGETS · 9

Target validation requirements in the pharmaceutical industry

2003 · Hans Winkler · TARGETS · 8

siRNA as a tool for streamlining functional genomic studies

2003 · Queta F. Boese, Stephen A. Scaringe, et al. · TARGETS · 8

Data integration standards in model organisms: from genotype to phenotype in the laboratory mouse

2002 · Carol J. Bult · TARGETS · 8

Using RNA interference to modulate gene expression

2002 · Maninder Chopra, Catherine Pachuk, et al. · TARGETS · 8

Curation is forever: comparative genomics approaches to functional annotation

2003 · Ross Overbeek, Domenica Devine, et al. · TARGETS · 7

Target validation using human tissue: from gene expression to function

2003 · Robert A. Coleman, Kenneth L. Clark · TARGETS · 6

Finding the molecules to fuel chemogenomics

2002 · Mark N. Namchuk · TARGETS · 6

Optimizing the production of animal models for target and lead validation

2002 · Patrick Fogarty · TARGETS · 6

Chemogenomics – pharmacology with genomics tools

2002 · Leslie J. Browne, L.Michael Furness, et al. · TARGETS · 6

Works count: 120

Citation count: 520

H-index: 12

I10-index: 15

2yr mean citedness: